Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) first reported in Wuhan has caused a global pandemic with dramatic health and socioeconomic consequences. The Coronavirus Disease 2019 (COVID-19) associated represents a challenge for health systems that had to quickly respond developing new diagnostic and therapeutic strategies. In the present work, we developed an “In House” ELISA with high sensitivity (92.2 %), specificity (100%) and precision (93.9%), with an area under the ROC curve (AUC) of 0.991, rendering the assay as an excellent serological test to correctly discriminate between SARS-COv-2 infected and non-infected individuals and study population seroprevalence. Among 758 patients evaluated for SARS-CoV-2 diagnosis in the province of Tucumán, Argentina, we found a Pearson correlation coefficient of 0.5048 between antibodies elicited against the RBD and the nucleocapsid (N) antigen. Additionally, 33.6% of individuals diagnosed with COVID-19 displayed mild levels of RBD-IgG antibodies, while 19% of the patients showed high antibody titers. Interestingly, patients with SARS-COV-2 infection over 60 years old elicited significantly higher levels of IgG antibodies against RBD compared to younger ones, while no difference was found between women and men. Surprisingly, individuals from a high altitude village displayed statistically significant higher and longer lasting anti-RBD antibodies compared to those from a city at a lower altitude, suggesting that a hypobaric hypoxia-adapted mechanism may act as a protective factor for COVID-19. To our knowledge, this is the first report correlating altitude with increased humoral immune response against SARS-Cov-2 infection.
Competing Interest Statement
SkyBio LLC supported the RBD production
Funding Statement
This work was supported by grants from SkyBIO LLC, and the School of Medicine of the UNT. We also acknowledge the partial support from Argentinean Research CouncilCONICET (PIP 722 and 806), Argentinean Research Agency (PICT-MINCYT3379, and PICT2018-02989), Tucuman National University Grant (PIUNT-UNT D644/1 and D624).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol used in the present study was opportunely submitted to the: -Comite de Etica en Investigacion- Direccion de Investigacion en Salud- SiProSa (Sistema Provincial de Salud). Address: Virgen de la Merced 189-1st floor- (San Miguel de Tucuman) −4000-Argentine. The protocol was approved by Research Department and Ethics Committee (SiProSa-Tucuman Health Ministery). Identification: Dictamen CEI 29-2020 Contact: +54-9-0381-4526585-ext:120 See all information at: https://msptucuman.gov.ar/wordpress/wpcontent/uploads/2021/03/03.Serocoversion-DICTAMEN-19-1-2021.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/Informed-Consent-COVITUC-RBD.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/PoryectoCOVITUC1.pdf
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be uploaded if required
Abbreviations
- RBD
- Receptor binding domain
- ROC
- receiver operating characteristic curve
- ELISA
- Enzyme linked immunosorbent assay
- mamsl
- meters above median sea level
